Mode
Text Size
Log in / Sign up

EGFR-TKI-resistant advanced lung adenocarcinoma

Part of Cancer

1 published article · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Cancer

Related studies from across the Cancer family.

Metabolic reprogramming of lipid-associated macrophages creates an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma
Allergy & Immunology Sys. Review
Metabolic reprogramming of lipid-associated macrophages creates an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma Specific immune cells help pancreatic cancer grow and spread
This narrative review characterizes the role of lipid-associated macrophages (LAMs) and their metabolic pathways in the pancreatic ductal ad…
Researchers identified how specific fat-loving immune cells create a shield that protects pancreatic tumors from the body's natural defenses…
Trastuzumab deruxtecan and pyrotinib provide disease control in lung squamous cell carcinoma with ERBB2 mutation
Drug Pipeline Guideline
Trastuzumab deruxtecan and pyrotinib provide disease control in lung squamous cell carcinoma with ERBB2 mutation New Treatment Strategy Shows Promise for Lung Squamous Cell Carcinoma
This case report describes a patient with stage IA2 lung squamous cell carcinoma and an ERBB2 exon 20 p.G776V mutation treated with trastuzu…
A new treatment plan using trastuzumab deruxtecan and pyrotinib showed promising results for a patient with a specific lung cancer mutation.
Serplulimab plus chemotherapy improves overall survival compared to chemotherapy alone in nsq-NSCLC
Oncology RCT
Serplulimab plus chemotherapy improves overall survival compared to chemotherapy alone in nsq-NSCLC Trial shows serplulimab improves survival in certain lung cancers
This Phase III randomized controlled trial of 636 treatment-naïve patients with locally advanced or metastatic nsq-NSCLC found that serpluli…
A new clinical trial shows that adding serplulimab to chemotherapy can extend life for patients with specific types of non-small cell lung c…
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Pulmonology & Critical Care RCT
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
Pulmonology & Critical Care Meta-analysis
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC ctDNA in blood predicts survival in advanced lung cancer
This systematic review and meta-analysis of 43 studies found that detectable or elevated baseline plasma ctDNA was associated with worse ove…
A blood test for tumor DNA can predict survival in advanced lung cancer, helping guide treatment decisions.
Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma
Infectious Disease Sys. Review
Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma Nanomedicine options for pancreatic cancer remain theoretical in current reviews
This narrative review surveys nanomedicine approaches for pancreatic ductal adenocarcinoma, including polymeric nanoparticles, small-molecul…
Current reviews suggest nanomedicine and other advanced therapies for pancreatic cancer are still theoretical concepts without proven clinic…
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications
Allergy & Immunology Sys. Review
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications Genetic changes in gut cancers may open new treatment doors for patients
This narrative review synthesizes evidence on KMT2C alterations across gastrointestinal malignancies. It links KMT2C dysfunction to transcri…
A review of genetic changes in gastrointestinal cancers suggests new ways to treat tumors by targeting specific DNA repair weaknesses.
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer
Drug Pipeline Guideline
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer One woman shows how alectinib shrinks lung cancer before surgery
This guideline-based case report describes a 57-year-old woman with ALK-rearranged stage IIIB lung cancer treated with neoadjuvant alectinib…
A single case shows alectinib shrinking lung cancer before surgery. This report offers hope for specific patients but needs more study.
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma
Infectious Disease Sys. Review
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma First patient achieves complete response with new ovarian cancer drug YL205
This is a single-patient case report of a 40-year-old woman with platinum-resistant, BRCA-wildtype high-grade serous ovarian carcinoma treat…
A single patient with advanced ovarian cancer achieved a complete response after 24 weeks of treatment with YL205, a new antibody-drug conju…
Narrative review outlines multimodal decision-making for EGFR-mutant NSCLC with leptomeningeal metastasis
Neurology Guideline
Narrative review outlines multimodal decision-making for EGFR-mutant NSCLC with leptomeningeal metastasis Doctors outline a pathway for treating lung cancer that spreads to the brain
This narrative review addresses patients with EGFR-mutant non-small cell lung cancer who develop resistance to tyrosine kinase inhibitors an…
This review outlines a clinical pathway to help physicians personalize treatment for lung cancer patients with brain spread.
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer
Drug Pipeline Meta-analysis
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer Darolutamide plus ADT improves survival in advanced prostate cancer patients
This systematic review and meta-analysis of randomized controlled trials evaluated darolutamide combination therapy versus placebo plus ADT …
A large analysis of trials shows darolutamide combined with standard treatment extends life and delays cancer spread in advanced prostate ca…
Case report and literature review on IgG4-related disease misdiagnosed as pancreatic cancer in a 70-year-old male
Rheumatology Meta-analysis
Case report and literature review on IgG4-related disease misdiagnosed as pancreatic cancer in a 70-year-old male A 70-year-old man avoided unnecessary surgery after doctors found a treatable autoimmune condition
This case report and literature review examines a 70-year-old male patient with IgG4-related autoimmune pancreatitis initially suspected as …
A 70-year-old man with a pancreatic mass was found to have a treatable autoimmune disease, sparing him from unnecessary surgery.